JP2012520059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012520059A5 JP2012520059A5 JP2011551304A JP2011551304A JP2012520059A5 JP 2012520059 A5 JP2012520059 A5 JP 2012520059A5 JP 2011551304 A JP2011551304 A JP 2011551304A JP 2011551304 A JP2011551304 A JP 2011551304A JP 2012520059 A5 JP2012520059 A5 JP 2012520059A5
- Authority
- JP
- Japan
- Prior art keywords
- functional protein
- binding partner
- protein
- item
- peptide mask
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 111
- 108090000623 proteins and genes Proteins 0.000 claims description 111
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 98
- 238000000034 method Methods 0.000 claims description 29
- 239000000758 substrate Substances 0.000 claims description 26
- 102000004190 Enzymes Human genes 0.000 claims description 24
- 108090000790 Enzymes Proteins 0.000 claims description 24
- 229940088598 enzyme Drugs 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 22
- 102000014150 Interferons Human genes 0.000 claims description 19
- 108010050904 Interferons Proteins 0.000 claims description 19
- 108010070047 Notch Receptors Proteins 0.000 claims description 16
- 102000005650 Notch Receptors Human genes 0.000 claims description 16
- 102000005962 receptors Human genes 0.000 claims description 13
- 108020003175 receptors Proteins 0.000 claims description 13
- 150000001413 amino acids Chemical group 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 108010047761 Interferon-alpha Proteins 0.000 claims description 9
- 102000006992 Interferon-alpha Human genes 0.000 claims description 9
- 108010091175 Matriptase Proteins 0.000 claims description 9
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims description 9
- 238000010494 dissociation reaction Methods 0.000 claims description 8
- 230000005593 dissociations Effects 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 108091035707 Consensus sequence Proteins 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 229940012957 plasmin Drugs 0.000 claims description 5
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 claims description 4
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 4
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 108010055066 asparaginylendopeptidase Proteins 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 150000008574 D-amino acids Chemical class 0.000 claims description 2
- 101000994439 Danio rerio Protein jagged-1a Proteins 0.000 claims description 2
- 102100036462 Delta-like protein 1 Human genes 0.000 claims description 2
- 102100036466 Delta-like protein 3 Human genes 0.000 claims description 2
- 102100033553 Delta-like protein 4 Human genes 0.000 claims description 2
- 108010088842 Fibrinolysin Proteins 0.000 claims description 2
- 101000928537 Homo sapiens Delta-like protein 1 Proteins 0.000 claims description 2
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims description 2
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims description 2
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 claims description 2
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 claims description 2
- 101000599613 Homo sapiens Interferon lambda receptor 1 Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102000002227 Interferon Type I Human genes 0.000 claims description 2
- 108010014726 Interferon Type I Proteins 0.000 claims description 2
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 claims description 2
- 102100026720 Interferon beta Human genes 0.000 claims description 2
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 claims description 2
- 102100037971 Interferon lambda receptor 1 Human genes 0.000 claims description 2
- 108090000467 Interferon-beta Proteins 0.000 claims description 2
- 102000008070 Interferon-gamma Human genes 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 108010072610 N-acetyl-gamma-glutamyl-phosphate reductase Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102100032702 Protein jagged-1 Human genes 0.000 claims description 2
- 102100032733 Protein jagged-2 Human genes 0.000 claims description 2
- 101710170213 Protein jagged-2 Proteins 0.000 claims description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 150000001576 beta-amino acids Chemical class 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 229940127276 delta-like ligand 3 Drugs 0.000 claims description 2
- 102000034238 globular proteins Human genes 0.000 claims description 2
- 108091005896 globular proteins Proteins 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 108010018844 interferon type III Proteins 0.000 claims description 2
- 108020001756 ligand binding domains Proteins 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 30
- 229920001184 polypeptide Polymers 0.000 claims 29
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108091005804 Peptidases Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 108010010648 interferon alfacon-1 Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 51
- 238000012216 screening Methods 0.000 description 8
- 210000005228 liver tissue Anatomy 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- -1 IFN-ω Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15473009P | 2009-02-23 | 2009-02-23 | |
| US61/154,730 | 2009-02-23 | ||
| PCT/US2010/025121 WO2010096838A2 (en) | 2009-02-23 | 2010-02-23 | Proproteins and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015146309A Division JP2015193653A (ja) | 2009-02-23 | 2015-07-24 | プロタンパク質およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012520059A JP2012520059A (ja) | 2012-09-06 |
| JP2012520059A5 true JP2012520059A5 (enExample) | 2012-12-06 |
| JP5861223B2 JP5861223B2 (ja) | 2016-02-16 |
Family
ID=42634501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011551304A Active JP5861223B2 (ja) | 2009-02-23 | 2010-02-23 | プロタンパク質およびその使用方法 |
| JP2015146309A Pending JP2015193653A (ja) | 2009-02-23 | 2015-07-24 | プロタンパク質およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015146309A Pending JP2015193653A (ja) | 2009-02-23 | 2015-07-24 | プロタンパク質およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (7) | US8399219B2 (enExample) |
| EP (1) | EP2398494A4 (enExample) |
| JP (2) | JP5861223B2 (enExample) |
| CN (1) | CN102481341B (enExample) |
| AU (2) | AU2010215761B2 (enExample) |
| BR (1) | BRPI1011384A2 (enExample) |
| CA (1) | CA2753294A1 (enExample) |
| RU (1) | RU2011138951A (enExample) |
| WO (1) | WO2010096838A2 (enExample) |
Families Citing this family (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8293685B2 (en) | 2007-07-26 | 2012-10-23 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| EP2190861A4 (en) * | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| CA2730068A1 (en) | 2008-07-07 | 2010-01-14 | Oxford Nanopore Technologies Limited | Base-detecting pore |
| US20110229877A1 (en) | 2008-07-07 | 2011-09-22 | Oxford Nanopore Technologies Limited | Enzyme-pore constructs |
| GB0820927D0 (en) | 2008-11-14 | 2008-12-24 | Isis Innovation | Method |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| EP2391732B1 (en) | 2009-01-30 | 2015-05-27 | Oxford Nanopore Technologies Limited | Methods using adaptors for nucleic acid constructs in transmembrane sequencing |
| CN102482330A (zh) * | 2009-01-30 | 2012-05-30 | 牛津纳米孔技术有限公司 | 酶突变体 |
| US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| GB0905140D0 (en) | 2009-03-25 | 2009-05-06 | Isis Innovation | Method |
| BR112013020411B1 (pt) | 2011-02-11 | 2021-09-08 | Oxford Nanopore Technologies Limited | Monômero de msp mutante, construto, polinucleotídeo, poro, kit e aparelho para caracterizar uma sequência de ácido nucleico alvo, e, método para caracterizar uma sequência de ácido nucleico alvo |
| KR20140050067A (ko) | 2011-07-25 | 2014-04-28 | 옥스포드 나노포어 테크놀로지즈 리미티드 | 막횡단 포어를 사용한 이중 가닥 폴리뉴클레오티드 서열분석을 위한 헤어핀 루프 방법 |
| CN104039979B (zh) | 2011-10-21 | 2016-08-24 | 牛津纳米孔技术公司 | 使用孔和Hel308解旋酶表征目标多核苷酸的酶方法 |
| CA2861808C (en) | 2011-12-29 | 2021-02-23 | Oxford Nanopore Technologies Limited | Enzyme method |
| EP2798083B1 (en) | 2011-12-29 | 2017-08-09 | Oxford Nanopore Technologies Limited | Method for characterising a polynucelotide by using a xpd helicase |
| WO2013153359A1 (en) | 2012-04-10 | 2013-10-17 | Oxford Nanopore Technologies Limited | Mutant lysenin pores |
| US11155860B2 (en) | 2012-07-19 | 2021-10-26 | Oxford Nanopore Technologies Ltd. | SSB method |
| CA2879355C (en) | 2012-07-19 | 2021-09-21 | Oxford Nanopore Technologies Limited | Helicase construct and its use in characterising polynucleotides |
| AU2013291763B2 (en) | 2012-07-19 | 2019-06-20 | Oxford Nanopore Technologies Limited | Modified helicases |
| EP2882844B1 (en) | 2012-08-10 | 2018-10-03 | Cytomx Therapeutics Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| US9791436B2 (en) | 2012-09-12 | 2017-10-17 | The University Of Queensland | Protease-based biosensor |
| CA2901545C (en) | 2013-03-08 | 2019-10-08 | Oxford Nanopore Technologies Limited | Use of spacer elements in a nucleic acid to control movement of a helicase |
| GB201314695D0 (en) | 2013-08-16 | 2013-10-02 | Oxford Nanopore Tech Ltd | Method |
| GB201313477D0 (en) | 2013-07-29 | 2013-09-11 | Univ Leuven Kath | Nanopore biosensors for detection of proteins and nucleic acids |
| SG11201509595PA (en) * | 2013-05-28 | 2015-12-30 | Dcb Usa Llc | Antibody locker for the inactivation of protein drug |
| WO2014197816A1 (en) * | 2013-06-06 | 2014-12-11 | Massachusetts Institute Of Technology | Stimulus responsive nanocomplexes and methods of use thereof |
| JP6693872B2 (ja) | 2013-07-25 | 2020-05-13 | シトムクス セラピューティクス，インコーポレイティド | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 |
| WO2015035452A1 (en) | 2013-09-12 | 2015-03-19 | The University Of Queensland | Bimolecular protease-based biosensor |
| KR20250051130A (ko) | 2013-09-25 | 2025-04-16 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| EP3575410A3 (en) | 2013-10-18 | 2020-03-04 | Oxford Nanopore Technologies Limited | Modified enzymes |
| GB201406151D0 (en) | 2014-04-04 | 2014-05-21 | Oxford Nanopore Tech Ltd | Method |
| EP3628328B1 (en) * | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| GB201403096D0 (en) | 2014-02-21 | 2014-04-09 | Oxford Nanopore Tech Ltd | Sample preparation method |
| US20170165334A1 (en) * | 2015-12-11 | 2017-06-15 | Tianxin Wang | Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification |
| SG11201608358VA (en) * | 2014-04-29 | 2016-11-29 | Novartis Ag | Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest |
| GB201417712D0 (en) | 2014-10-07 | 2014-11-19 | Oxford Nanopore Tech Ltd | Method |
| US10443097B2 (en) | 2014-05-02 | 2019-10-15 | Oxford Nanopore Technologies Ltd. | Method of improving the movement of a target polynucleotide with respect to a transmembrane pore |
| ES2913205T3 (es) | 2014-05-13 | 2022-06-01 | Bioatla Inc | Proteínas biológicas activas condicionalmente |
| WO2016004383A1 (en) | 2014-07-03 | 2016-01-07 | City Of Hope | Tumor-selective ctla-4 antagonists |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| CN119899249A (zh) | 2014-09-01 | 2025-04-29 | 弗拉芒区生物技术研究所 | 突变csgg孔 |
| US10266885B2 (en) | 2014-10-07 | 2019-04-23 | Oxford Nanopore Technologies Ltd. | Mutant pores |
| GB201418159D0 (en) | 2014-10-14 | 2014-11-26 | Oxford Nanopore Tech Ltd | Method |
| WO2016115275A1 (en) | 2015-01-13 | 2016-07-21 | City Of Hope | Ctla4-binding protein peptide-linker masks |
| IL300408B2 (en) | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| EP3778640A1 (en) | 2015-05-01 | 2021-02-17 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
| JP6857875B2 (ja) * | 2015-05-19 | 2021-04-14 | 国立大学法人 熊本大学 | 新規な細胞膜透過性ペプチド |
| EP3310811B1 (en) | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
| EA034582B1 (ru) | 2015-08-07 | 2020-02-21 | АЭлЭкс ОНКОЛОДЖИ ИНК. | Конструкции варианта sirp-альфа и их применение |
| US10758886B2 (en) * | 2015-09-14 | 2020-09-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Conditioned surfaces for in situ molecular array synthesis |
| MA43134A (fr) | 2015-10-30 | 2018-09-05 | Aleta Biotherapeutics Inc | Compositions et méthodes de transduction tumorale |
| WO2017075537A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| HUE054131T2 (hu) | 2015-11-19 | 2021-08-30 | Revitope Ltd | Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben |
| TW201731532A (zh) | 2016-02-05 | 2017-09-16 | 伊繆諾金公司 | 用於製備細胞結合劑-細胞毒性劑結合物之有效方法 |
| JP7015244B2 (ja) * | 2016-03-22 | 2022-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | プロテアーゼ活性化ｔ細胞二重特異性分子 |
| EP3464616B1 (en) | 2016-05-25 | 2022-05-04 | Oxford Nanopore Technologies plc | Method |
| GB201609220D0 (en) | 2016-05-25 | 2016-07-06 | Oxford Nanopore Tech Ltd | Method |
| MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| JP2020528878A (ja) * | 2017-06-20 | 2020-10-01 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | がん治療用インターフェロンプロドラッグ |
| WO2019036433A2 (en) | 2017-08-16 | 2019-02-21 | Bristol-Myers Squibb Company | ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION |
| CN111247171A (zh) | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| CN112005304A (zh) | 2018-03-20 | 2020-11-27 | 西托姆克斯治疗公司 | 用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法 |
| TW202010757A (zh) | 2018-04-11 | 2020-03-16 | 美商英伊布里克斯公司 | 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途 |
| US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| GB201807793D0 (en) | 2018-05-14 | 2018-06-27 | Oxford Nanopore Tech Ltd | Method |
| WO2019222296A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| MX2020012251A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| MX2020014290A (es) | 2018-06-22 | 2021-08-05 | Cugene Inc | Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos. |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| CN113286812B (zh) | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| AU2019356573B2 (en) | 2018-10-11 | 2025-12-18 | Inhibrx Biosciences, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
| CN113166261A (zh) | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | B7h3单域抗体及其治疗性组合物 |
| US12590169B2 (en) | 2018-10-11 | 2026-03-31 | Inhibrx Biosciences, Inc. | 5T4 single domain antibodies and therapeutic compositions thereof |
| JP7611820B2 (ja) | 2018-10-11 | 2025-01-10 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Ｄｌｌ３シングルドメイン抗体およびその治療用組成物 |
| JP2022512124A (ja) | 2018-12-06 | 2022-02-02 | シートムエックス セラピューティクス，インコーポレイテッド | マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法 |
| WO2020123980A1 (en) * | 2018-12-14 | 2020-06-18 | Proviva Therapeutics (Hong Kong) Limited | Il-15 compositions and methods of use thereof |
| JP7518549B2 (ja) * | 2019-02-02 | 2024-07-18 | シャンハイテック ユニバーシティ | 遺伝子編集における非意図的な変異の阻害 |
| CA3136602A1 (en) * | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
| BR112021022666A2 (pt) | 2019-05-14 | 2022-03-29 | Werewolf Therapeutics Inc | Frações de separação e seus métodos e uso |
| CA3141130A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| CN114341189A (zh) | 2019-06-12 | 2022-04-12 | 奥美药业有限公司 | 全新il-15前药及其应用 |
| WO2021055568A1 (en) * | 2019-09-19 | 2021-03-25 | Proviva Therapeutics (Hong Kong) Limited | Il-2 compositions and methods of use thereof |
| FI4034170T3 (fi) | 2019-10-23 | 2026-04-16 | Cue Biopharma Inc | Tgf-beta-polypeptidejä |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| WO2021108693A1 (en) | 2019-11-27 | 2021-06-03 | ALX Oncology Inc. | Combination therapies for treating cancer |
| AU2021205981A1 (en) | 2020-01-11 | 2022-07-14 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| EP4097129A1 (en) | 2020-01-29 | 2022-12-07 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
| WO2021158907A1 (en) * | 2020-02-06 | 2021-08-12 | Aetio Biotherapy, Inc. | Compositions and methods for treating viral infections |
| WO2021207657A1 (en) | 2020-04-09 | 2021-10-14 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2022109399A1 (en) * | 2020-11-23 | 2022-05-27 | Cue Biopharma, Inc. | Tgf-beta polypeptides |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| KR20230157448A (ko) * | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| KR20240021943A (ko) * | 2021-06-18 | 2024-02-19 | 남미 테라퓨틱스, 인크. | 암의 치료에 사용하기 위한 마스킹된 유형 I 인터페론 (IFNα 및 IFNβ)을 포함하는 융합 단백질 조성물(들) 및 그의 방법 |
| EP4387987A2 (en) * | 2021-08-18 | 2024-06-26 | Werewolf Therapeutics, Inc. | Activatable inteferon polypeptides and methods of use thereof |
| MX2024004301A (es) | 2021-10-08 | 2024-04-26 | Cytomx Therapeutics Inc | Construcciones de citocinas activables y metodos combinados. |
| WO2023060156A2 (en) | 2021-10-08 | 2023-04-13 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| JP2024538042A (ja) | 2021-10-13 | 2024-10-18 | シートムエックス セラピューティクス，インコーポレイテッド | 三量体活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
| JP2025512798A (ja) | 2022-03-25 | 2025-04-22 | サイトムエックス セラピューティクス，インク． | 活性化可能な二重アンカー型マスク化分子及びその使用方法 |
| EP4504782A2 (en) | 2022-04-01 | 2025-02-12 | CytomX Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
| WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| AR130077A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Substratos escindibles por proteasas, y métodos de uso de los mismos |
| JP2025525868A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| US20260015425A1 (en) | 2022-08-01 | 2026-01-15 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| WO2024030845A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| TW202424184A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割部分及其使用方法 |
| CN120958015A (zh) | 2023-04-12 | 2025-11-14 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| EP4694934A1 (en) | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2025007062A1 (en) * | 2023-06-30 | 2025-01-02 | The Regents Of The University Of California | Pro-polypeptides and methods of using and designing the same |
| TW202517789A (zh) * | 2023-07-04 | 2025-05-01 | 香港商禮邦醫藥（香港）有限公司 | Ｋｌｋ１融合蛋白質的製備方法 |
| KR20260056204A (ko) | 2023-08-14 | 2026-04-24 | 보로 테라퓨틱스, 인코포레이티드 | 표적 세포에 대한 골수 세포 활성을 조건부로 촉진시키는 치료용 결합제 및 이의 용도 |
| CN116930512B (zh) * | 2023-09-19 | 2024-01-05 | 细胞生态海河实验室 | 一种用于脑卒中再发风险分析的生物标志物及其应用 |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026024841A1 (en) | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
| WO2026117686A1 (en) | 2024-11-27 | 2026-06-04 | Nammi Therapeutics, Inc. | FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF |
Family Cites Families (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| JPS5686121A (en) | 1979-12-14 | 1981-07-13 | Teijin Ltd | Antitumor proten complex and its preparation |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5306731A (en) | 1985-06-14 | 1994-04-26 | Massachusetts Eye And Ear Infirmary | Method and products for treating the eye |
| US5849478A (en) | 1986-08-14 | 1998-12-15 | Cashman; Daniel P. | Blocked-polymerase polynucleotide immunoassay method and kit |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US4952394A (en) | 1987-11-23 | 1990-08-28 | Bristol-Myers Company | Drug-monoclonal antibody conjugates |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5322678A (en) | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
| US5144012A (en) | 1988-08-08 | 1992-09-01 | Eli Lilly And Company | Cytotoxic drug conjugates |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5010176A (en) | 1988-11-10 | 1991-04-23 | Eli Lilly And Company | Antibody-drug conjugates |
| US5162218A (en) | 1988-11-18 | 1992-11-10 | The Regents Of The University Of California | Conjugated polypeptides and methods for their preparation |
| JPH04504713A (ja) | 1988-11-18 | 1992-08-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 共役ポリペプチドとその調製および使用方法 |
| KR0162259B1 (ko) | 1989-12-05 | 1998-12-01 | 아미 펙터 | 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체 |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5272253A (en) | 1991-07-01 | 1993-12-21 | Eli Lilly And Company | Cluster conjugates of drugs with antibodies |
| US6107059A (en) | 1992-04-29 | 2000-08-22 | Affymax Technologies N.V. | Peptide library and screening method |
| CA2145278C (en) | 1992-09-25 | 2009-03-10 | Commonwealth Scientific And Industrial Research Organisation | Target binding polypeptide |
| US5834247A (en) | 1992-12-09 | 1998-11-10 | New England Biolabs, Inc. | Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein |
| WO1994018221A1 (en) | 1993-02-02 | 1994-08-18 | The Scripps Research Institute | Methods for producing polypeptide binding sites |
| US5679548A (en) | 1993-02-02 | 1997-10-21 | The Scripps Research Institute | Methods for producing polypeptide metal binding sites and compositions thereof |
| US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
| GB9322156D0 (en) | 1993-10-27 | 1993-12-15 | Univ Newcastel Upon Tyne | Activation of molecules |
| US5733757A (en) | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| US5468785A (en) | 1994-04-15 | 1995-11-21 | University Of Akron | Cobaloxime photoinitiated free radical polymerizations |
| DE69535665T2 (de) | 1994-08-19 | 2009-04-02 | La Region Wallonne | Konjugate enthaltend ein antitumorales mittel und deren verwendung |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP0871673B1 (en) | 1995-05-03 | 2006-04-05 | Bioenhancementsments Ltd. | Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety |
| US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| ATE239041T1 (de) | 1996-02-09 | 2003-05-15 | Basf Ag | Humane antikörper welche an humanen tnfalpha binden |
| GB9603507D0 (en) | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
| US5866341A (en) | 1996-04-03 | 1999-02-02 | Chugai Pharmaceutical Co., Ltd. | Compositions and methods for screening drug libraries |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US5990286A (en) | 1996-12-18 | 1999-11-23 | Techniclone, Inc. | Antibodies with reduced net positive charge |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US20070059302A1 (en) | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
| US6323322B1 (en) | 1997-04-30 | 2001-11-27 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1998052966A1 (en) | 1997-05-19 | 1998-11-26 | The Johns Hopkins University School Of Medecine | Tissue specific prodrug |
| AU8513198A (en) | 1997-07-25 | 1999-02-16 | Du Pont Pharmaceuticals Company | Aggrecan degrading metallo proteases |
| US20030082767A1 (en) | 1997-09-18 | 2003-05-01 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| WO2000004192A1 (en) | 1998-07-17 | 2000-01-27 | Emory University | Methods for detecting and mapping genes, mutations and variant polynucleotide sequences |
| US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| US6203989B1 (en) | 1998-09-30 | 2001-03-20 | Affymetrix, Inc. | Methods and compositions for amplifying detectable signals in specific binding assays |
| US6180343B1 (en) | 1998-10-08 | 2001-01-30 | Rigel Pharmaceuticals, Inc. | Green fluorescent protein fusions with random peptides |
| AU766190B2 (en) | 1998-10-16 | 2003-10-09 | Biogen Idec Ma Inc. | Interferon-beta fusion proteins and uses |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US6015557A (en) | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| AU779402B2 (en) | 1999-04-12 | 2005-01-20 | Genentech Inc. | Tumor necrosis factor homologs and nucleic acids encoding the same |
| IL129427A0 (en) * | 1999-04-13 | 2000-02-17 | Yeda Res & Dev | Preparation of biologically active molecules |
| EP1179541B1 (en) | 1999-04-28 | 2004-06-16 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| US6268488B1 (en) | 1999-05-25 | 2001-07-31 | Barbas, Iii Carlos F. | Prodrug activation using catalytic antibodies |
| US6903196B1 (en) | 1999-06-17 | 2005-06-07 | Utah Ventures Ii, L.P. | Methods for identifying and isolating tissue-specific lumen-exposed molecules |
| US20040146516A1 (en) | 1999-06-17 | 2004-07-29 | Utah Ventures Ii L.P. | Lumen-exposed molecules and methods for targeted delivery |
| JP2003508028A (ja) | 1999-07-28 | 2003-03-04 | ジェネンテック・インコーポレーテッド | 腫瘍治療のための組成物と方法 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US20050208558A1 (en) | 1999-10-19 | 2005-09-22 | Applera Corporation | Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof |
| DE19952956A1 (de) | 1999-11-03 | 2001-05-17 | Acgt Progenomics Ag | Verfahren zur Verbindung von molekularen Substanzen |
| US6548248B1 (en) * | 1999-11-10 | 2003-04-15 | Propper Manufacturing Co., Inc. | DNA sterilization indicator |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| EP1278853A2 (en) * | 2000-04-11 | 2003-01-29 | Institut Pasteur | Listeria monocytogenes genome, polypeptides and uses |
| US7514067B2 (en) | 2000-04-25 | 2009-04-07 | President And Fellows Of Harvard College | Methods for tumor diagnosis and therapy |
| US20040181830A1 (en) * | 2001-05-07 | 2004-09-16 | Kovalic David K. | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| CA2408103A1 (en) * | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds and methods of making and using the same |
| EP1286700A2 (en) * | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| US20040014652A1 (en) | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| US6625945B2 (en) | 2000-08-08 | 2003-09-30 | Alfred D. Commins | Balanced, multi-stud hold-down |
| DE10045592A1 (de) | 2000-09-15 | 2002-03-28 | Klaus Pfizenmaier | Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| JP4334866B2 (ja) | 2000-10-09 | 2009-09-30 | アイシス イノヴェイション リミテッド | 治療用抗体 |
| EP1349943A2 (en) | 2001-01-04 | 2003-10-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Detection of protein conformation using a split ubiquitin reporter system |
| US7141392B2 (en) | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20040097586A1 (en) | 2001-01-30 | 2004-05-20 | Andre Trouet | Anti-tumor compounds |
| PL362324A1 (en) | 2001-02-19 | 2004-10-18 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| WO2002066058A1 (en) | 2001-02-19 | 2002-08-29 | Merck Patent Gmbh | Modified anti-egfr antibodies with reduced immunogenicity |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| GB0118155D0 (en) | 2001-07-25 | 2001-09-19 | Lorantis Ltd | Superantigen |
| EP1410018A1 (en) * | 2001-07-25 | 2004-04-21 | Lorantis Limited | Method for detecting modultators of notch signalling |
| AU2002317333C1 (en) | 2001-08-01 | 2009-06-25 | University Of Bristol | VEGF isoform |
| US20030082191A1 (en) | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20030134824A1 (en) | 2001-11-12 | 2003-07-17 | Ronald Breslow | Beta-cyclodextrin dimers and phthalocyanines and uses thereof |
| CA2470643C (en) | 2001-12-17 | 2011-10-18 | Bryan Paul Morgan | Cleavable reagents for specific delivery to disease sites |
| CA2475388A1 (en) * | 2002-02-14 | 2003-08-21 | William J. Rutter | Chimeric molecules for cleavage in a treated host |
| NZ536420A (en) | 2002-04-12 | 2008-04-30 | Medarex Inc | Methods of treatment using CTLA-4 antibodies |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| WO2004021861A2 (en) | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| JP4351430B2 (ja) | 2002-10-04 | 2009-10-28 | 財団法人癌研究会 | ナノ黒鉛構造体に結合能を有するペプチド |
| CA2508831C (en) | 2002-12-13 | 2012-05-01 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| CN1548537B (zh) | 2002-12-27 | 2010-05-05 | 深圳市源兴生物医药科技有限公司 | 疫苗制备方法和抗肿瘤疫苗 |
| EP1635858A4 (en) | 2003-05-29 | 2009-08-26 | Scripps Research Inst | TARGETED DELIVERY TO LEGUMAIN EXPRESSING CELLS |
| US20050009110A1 (en) | 2003-07-08 | 2005-01-13 | Xiao-Jia Chang | Methods of producing antibodies for diagnostics and therapeutics |
| JP2007501011A (ja) * | 2003-08-01 | 2007-01-25 | ジェネンテック・インコーポレーテッド | 制限多様性配列を有する結合型ポリペプチド |
| ATE447611T1 (de) | 2003-08-18 | 2009-11-15 | Univ California | Polypeptid-display-bibliotheken und verfahren zur herstellung und verwendung davon |
| US20050106100A1 (en) | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
| US7431915B2 (en) | 2003-10-31 | 2008-10-07 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| US7985401B2 (en) | 2003-10-31 | 2011-07-26 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| US20050255042A1 (en) | 2003-11-24 | 2005-11-17 | The Regents Of The University Of California Office Of Technology Transfer, University Of California | On-demand cleavable linkers for radioconjugates for cancer imaging and therapy |
| WO2005067980A2 (en) | 2004-01-12 | 2005-07-28 | Pointilliste, Inc. | Design of therapeutics and therapeutics |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| GB0404187D0 (en) | 2004-02-25 | 2004-03-31 | Biotransformations Ltd | Binding agents |
| EP1579873A1 (en) | 2004-03-23 | 2005-09-28 | Complex Biosystems GmbH | Polymeric prodrugs |
| US7541330B2 (en) | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
| CA2587424A1 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
| US20090022782A1 (en) | 2005-02-25 | 2009-01-22 | National University Corp. Hokkaido University | Blood Retainable Device Exhibiting Selective Degradability in Tumor Tissue |
| JP5137814B2 (ja) | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート |
| DE102005036542A1 (de) | 2005-08-03 | 2007-02-08 | Universität Stuttgart | CTL-Prodrug |
| WO2007027935A2 (en) | 2005-08-31 | 2007-03-08 | The Regents Of The University Of California | Cellular libraries of peptide sequences (clips) and methods of using the same |
| US20090130776A1 (en) | 2005-09-01 | 2009-05-21 | Canon Kabushiki Kaisha | Binding protein molecule |
| JP4567563B2 (ja) | 2005-09-22 | 2010-10-20 | 富士通株式会社 | 携帯端末装置、ヒンジ装置、筒状部材及び光通信システム |
| EP1770099A1 (en) | 2005-09-28 | 2007-04-04 | University of Geneva | Method of producing a modified (poly)peptide |
| EP1966242A1 (en) | 2005-12-06 | 2008-09-10 | Domantis Limited | Ligands that have binding specificity for egfr and/or vegf and methods of use therefor |
| GB0604187D0 (en) * | 2006-03-02 | 2006-04-12 | Fusion Antibodies Ltd | Peptide and uses thereof |
| US20090246142A1 (en) | 2006-03-10 | 2009-10-01 | Massachusetts Institute Of Technology | Triggered Self-Assembly of Nanoparticles In Vivo |
| EP1993608A1 (en) | 2006-03-10 | 2008-11-26 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
| EA015992B1 (ru) | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
| JP4959226B2 (ja) * | 2006-05-19 | 2012-06-20 | 独立行政法人産業技術総合研究所 | スリーフィンガー様蛋白質ライブラリ |
| US8338482B2 (en) * | 2006-07-20 | 2012-12-25 | Wisconsin Alumni Research Foundation | Modulating notch1 signaling pathway for treating neuroendocrine tumors |
| WO2008048680A2 (en) * | 2006-10-19 | 2008-04-24 | Maine Medical Center Research Institute | Notch 2 signaling as a breast cancer suppressor pathway |
| EP1930342B1 (en) * | 2006-12-04 | 2012-01-25 | Institut Pasteur | OB-fold used as scaffold for engineering new specific binders |
| EP2178896A1 (en) | 2007-07-31 | 2010-04-28 | The Johns Hopkins University | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| EP2190861A4 (en) * | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| ES2536772T3 (es) | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| EA021967B1 (ru) | 2008-01-03 | 2015-10-30 | Дзе Скриппс Рисерч Инститьют | Доставка антител посредством модульного домена распознавания |
| US20100189727A1 (en) | 2008-12-08 | 2010-07-29 | Tegopharm Corporation | Masking Ligands For Reversible Inhibition Of Multivalent Compounds |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| CA3136602A1 (en) * | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
-
2010
- 2010-02-23 US US12/711,199 patent/US8399219B2/en not_active Expired - Fee Related
- 2010-02-23 AU AU2010215761A patent/AU2010215761B2/en not_active Ceased
- 2010-02-23 WO PCT/US2010/025121 patent/WO2010096838A2/en not_active Ceased
- 2010-02-23 CN CN201080017140.XA patent/CN102481341B/zh not_active Expired - Fee Related
- 2010-02-23 BR BRPI1011384A patent/BRPI1011384A2/pt active Search and Examination
- 2010-02-23 RU RU2011138951/10A patent/RU2011138951A/ru not_active Application Discontinuation
- 2010-02-23 JP JP2011551304A patent/JP5861223B2/ja active Active
- 2010-02-23 CA CA2753294A patent/CA2753294A1/en not_active Abandoned
- 2010-02-23 EP EP10744488.7A patent/EP2398494A4/en not_active Withdrawn
-
2012
- 2012-12-20 US US13/721,528 patent/US8993266B2/en active Active
-
2015
- 2015-03-30 US US14/673,175 patent/US9644016B2/en active Active
- 2015-07-24 JP JP2015146309A patent/JP2015193653A/ja active Pending
-
2017
- 2017-03-10 AU AU2017201682A patent/AU2017201682A1/en not_active Abandoned
- 2017-05-08 US US15/589,464 patent/US10513549B2/en not_active Expired - Fee Related
-
2019
- 2019-11-11 US US16/680,279 patent/US20200308243A1/en not_active Abandoned
-
2022
- 2022-03-21 US US17/699,846 patent/US20230035290A1/en not_active Abandoned
- 2022-12-19 US US18/068,104 patent/US20230183308A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011138951A (ru) | Пропротеины и способы их применения | |
| JP7125453B2 (ja) | 生物活性カーゴの経口送達のためのコリックス毒素由来融合分子 | |
| JP2023518518A5 (enExample) | ||
| CA2304254A1 (en) | Trimerising module | |
| JP2018171063A5 (enExample) | ||
| US10617741B2 (en) | Compositions and methods for oral delivery of therapeutic cargo | |
| JP2023553697A5 (enExample) | ||
| JP2011501951A5 (enExample) | ||
| JP2004508828A (ja) | 標的−特異的プロドラッグとしての使用のための抗体サイトカイン−サイトカインインヒビター（セレクトカイン）からの融合タンパク質 | |
| CN115867310A (zh) | 用于治疗癌症的识别kras g12d的抗cd3的可溶性tors和融合物 | |
| JP2022551918A5 (enExample) | ||
| CN115175920A (zh) | 加条形码的xten多肽及其组合物以及其制备和使用方法 | |
| US20240207372A1 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| JP2024069465A5 (enExample) | ||
| CA3180251A1 (en) | Cytokine conjugates | |
| CN113874393A (zh) | 对hbv包膜蛋白具有特异性的结合分子 | |
| CN100400664C (zh) | 肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法 | |
| TH45967A (th) | โมเลกุลที่เกี่ยวข้องกับแอนจิโอเจเนซิส |